Preprint Review Version 2 This version is not peer-reviewed

Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients

Version 1 : Received: 21 October 2024 / Approved: 21 October 2024 / Online: 21 October 2024 (12:37:38 CEST)
Version 2 : Received: 29 October 2024 / Approved: 29 October 2024 / Online: 30 October 2024 (05:04:22 CET)

How to cite: Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints 2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v2 Min, C.; Zhong, X.; Cui, Y.; Zhang, H.; Wang, Q. Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma Patients. Preprints 2024, 2024101578. https://doi.org/10.20944/preprints202410.1578.v2

Abstract

Over the past few decades, the landscape for multiple myeloma (MM) therapy has significantly advanced, largely due to the approval and introduction of new-generation proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Despite these advancements, MM remains incurable. In March 2021, the U.S. FDA approved the chimeric antigen receptor T-cell (CAR-T) therapy idecabtagene vicleucel (ide-cel) for relapsed/refractory multiple myeloma (R/R MM), heralding the advent of cellular therapies for R/R MM. However, due to factors such as the downregulation or loss of tumor antigen expression, T-cell exhaustion, and the influence of the tumor immune microenvironment, most R/R MM patients inevitably experience relapse following CAR-T cell therapy. Consequently, salvage therapy in the post-CAR-T setting has emerged as a critical area of research. This review discusses the potential factors leading to CAR-T therapy failure in R/R MM patients and discusses subsequent salvage therapeutic strategies, offering recommendations for addressing treatment failure in this context.

Keywords

Multiple Myeloma; Chimeric Antigen Receptor T-cells; Cellular Therapy Failure; Salvage Therapy

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.